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Abstract: The Epstein–Barr virus (EBV), Kaposi sarcoma herpesvirus (KSHV) and human T-
lymphotropic virus (HTLV-1) are lymphomagenic viruses with region-specific induced morbidity. 
The RIAL-CYTED aims to increase the knowledge of lymphoma in Latin America (LA), and, as 
such, we systematically analyzed the literature to better understand our risk for virus-induced 
lymphoma. We observed that high endemicity regions for certain lymphomas, e.g., Mexico and 
Peru, have a high incidence of EBV-positive lymphomas of T/NK cell origin. Peru also carries the 
highest frequency of EBV-positive classical Hodgkin lymphoma (HL) and EBV-positive diffuse 
large B cell lymphoma, not otherwise specified (NOS), than any other LA country. Adult T cell 
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lymphoma is endemic to the North of Brazil and Chile. While only few cases of KSHV-positive 
lymphomas were found, in spite of the close correlation of Kaposi sarcoma and the prevalence of 
pathogenic types of KSHV. Both EBV-associated HL and Burkitt lymphoma mainly affect young 
children, unlike in developed countries, in which adolescents and young adults are the most 
affected, correlating with an early EBV seroconversion for LA population despite of lack of 
infectious mononucleosis symptoms. High endemicity of KSHV and HTLV infection was observed 
among Amerindian populations, with differences between Amazonian and Andean populations. 
Keywords: Epstein–Barr virus; Kaposi sarcoma herpesvirus; human T-lymphotropic virus; 
lymphoma; Latin America 
 
1. Introduction 
Neoplasms of an infectious etiology account for about 16% of all cancers, which amounts to 
about two million cases per year, considering virus-, bacteria- and parasite-derived cancers. 
Interestingly, this number is significantly higher for developing countries, in which it can be as high 
as 30%, while in highly industrialized countries, such as the US, it can be as low as 5% [1]. The bases 
for this difference are not clear, but it may be due to the prevalence of the oncogenic infectious agents, 
or to additional co-factors causally linked to the infectious neoplasms. 
Virus-derived cancers almost always originate from established chronic viral infections, because 
the mechanisms of viral persistence in the infected host are compatible with oncogenesis. Indeed, all 
human oncogenic viruses express proteins, and/or non-coding RNAs with the capacity to transform 
cells in culture and induce cancer in transgenic animals [2]. Viral oncogenes tend to enhance cell 
proliferation and survival, aiming to maintain the pool of infected cells during persistent infections. 
The International Agency for Research on Cancer (IARC) acknowledges seven viruses as direct 
human oncogenic agents: the Epstein–Barr virus (EBV), Kaposi sarcoma herpesvirus (KSHV), human 
T cell lymphotropic virus type 1 (HTLV-1), high risk human papillomaviruses (HPV), hepatitis B 
virus (HBV), hepatitis C virus (HCV) and Merkel cell polyomavirus (MCPyV) [3]. Although the 
human immunodeficiency virus (HIV) is also causally associated with several neoplasms, it is as an 
indirect oncogenic agent, due to the immunosuppression it imposes upon the infected host. 
The Epstein–Barr virus (EBV) was the first oncogenic virus discovered 56 years ago by Dr. 
Anthony Epstein and Dr. Ivonne Barr. EBV was initially observed in samples of Burkitt lymphoma 
(BL) coming from the equatorial Africa, which represents the perfect example of the unequal 
geographical distribution of neoplasms of infectious origin. While EBV is responsible for close to 
100% of the BL originating in this region, EBV only accounts for about 20% of all BLs in developed 
countries (see below). We later understood that whilst EBV is evenly distributed around the world, 
the African BL is also associated with repetitive infections with Plasmodium falciparum, an 
important co-factor of this neoplasm and a parasite endemic to this area. Today, BL is classified 
within three distinct clinical types, endemic (malaria- and EBV-associated), sporadic (derived from 
areas in which malaria is not holoendemic) and immunodeficiency-associated [4]. 
The world distribution of the oncogenic viruses varies significantly, while most adults are 
already infected with EBV, HPV and MCPyV indistinct of the geographic region, the others tend to 
be more prevalent in specific populations [2]. Even today, despite the global means of transportation 
and increased immigration that have allowed a more heterogeneous mix of populations, the 
prevalence of KSHV and HTLV-1 infection is still restricted to particular geographical areas, implying 
mechanisms of viral persistence in the population that are not explained by mere socioeconomic 
factors, but in which genetic susceptibilities, ethnic origin, culture and the prevalence of co-factors 
may be critical (see below). Like EBV, KSHV and HTLV-1 are associated with lymphoid neoplasms 
[2]. While EBV mainly infects and persists in B cells, KSHV and HTLV-1 persist in B cells and T cells, 
respectively, and, as such, they have been associated with B and T cell lymphomas [2]. 
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Latin America (LA) comprises the land from Mexico to Argentina and the Spanish speaking 
Caribbean, countries with a complex mix of geographies, climates, politics, cultures, ethnicities and 
different levels of socioeconomic development, and, in which, a high prevalence of oncogenic viruses, 
acute tropical diseases and malnourishment collide. Early epidemiological studies documented a 
high seroprevalence of KSHV and HTLV-1 in some regions of LA, and to this day, it is common to 
find in the scientific literature that these viruses are endemic to LA (see below). However, the loco-
regional estimation of their prevalence and induced morbidity remains poorly known. The RIAL-
CYTED harbors a multidisciplinary Ibero-American network of clinical and basic researchers created 
to form a platform of multi-center cooperation focusing on increasing our knowledge of lymphoma, 
particularly for more underdeveloped or developing regions. This network aims to improve the 
diagnosis and prognosis of these neoplasms throughout LA by way of homogenizing its 
identification and classification. With that purpose, in this review, we sought to systematically 
organize and analyze the literature related to the lymphotropic and lymphomagenic viruses EBV, 
KSHV and HTLV-1, in order to better understand their loco-regional distribution and the risk our 
population carries in terms of developing lymphoma. 
To this end, we explored three web search engines, PubMed, Google Scholar and SciELO, to 
access all related scientific publications in English, Portuguese and Spanish. Searches were done with 
the name of each LA country plus the name of each virus individually: Epstein–Barr virus or EBV; 
KSHV, KSV, HHV8 or Kaposi sarcoma virus; HTLV-1, ATLV or human T-cell lymphoma virus 1. All 
collected publications were read and classified according to the content; sero-epidemiological studies 
of KSHV and HTLV-1 viruses were considered, in order to discuss their association with lymphoma 
in specific regions, while EBV sero-epidemiological studies were discarded, since it is well known 
that there is a worldwide high prevalence in both developed and developing countries. In case 
reports and when series of lymphomas were included, we assessed the methods of viral diagnosis, 
prioritizing those studies in which the presence of the virus was addressed in the lymphoma sample 
by means of immune or molecular methods. The search was carried out from February 2019 to 
December 2019, and, although we aimed to include all papers found, regardless of the date of 
publication, many journals do not have online versions of the documents prior to the 1990s. 
Moreover, many old studies did not comply with more recent lymphoma classification. The results 
are disclosed in the next sections for each particular virus. 
2. Epstein–Barr Virus 
EBV is a human gamma-1 herpesvirus usually persisting as a harmless passenger; its growth-
transforming ability is linked to a range of lymphoproliferative lesions and malignant lymphomas 
[5]. EBV-associated lymphomas vary according to the geographic location, age, sex, genetic 
background and socioeconomic condition [6]. Additionally, the age of primary infection varies 
substantially worldwide, correlating with socioeconomic factors [7]. In underdeveloped and 
developing populations, EBV infection is acquired at a young age and is usually asymptomatic. A 
delay in acquiring primary infection until adolescence or young adulthood, which usually occurs in 
more developed countries, can manifest as infectious mononucleosis (IM) in 25–75% of the late 
infected persons [8]. 
EBV infection has been associated with the following lymphomas in addition to BL: Hodgkin 
lymphoma (HL), lymphomas in immunosuppressed individuals (post-transplant lymphoproliferative 
disorders (PTLD) and HIV-associated lymphoproliferative disorders and T-cell and NK-cell lymphomas) 
[3]. Furthermore, the last WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues 
included two new entities specifically associated with EBV: EBV-positive diffuse large B-cell lymphoma 
(DLBCL) not otherwise specified (NOS) and systemic EBV-positive T-cell lymphoma of childhood [9]. 
Since the incidence of HIV- and transplant-related lymphoma is more informative of the HIV prevalence 
or the number of transplanted patients than of the EBV distribution, we will not cover them in this review. 
See Table 1 for the studies considered and the frequency of EBV association. 
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Table 1. Summary of studies about Epstein–Barr virus (EBV) associated lymphomas. 
Country (Ref) Lymphoma Type 
Type of 
Study 
Methods EBV Association 
Description of the Study 
Argentina [10–12] DLBCL (ad/ped) Cohort ISH, IHC 12.6% (12/95) 
26 DLBCL ped; 69 DLBCL ad from Buenos Aires, Argentina. EBV prevalence 
72% ped. 




1 PBL in HIV+ patient from Buenos Aires, Argentina. 
Argentina [14] BL (ped) Cohort ISH, IHC 29% IHC (7/24); 100% ISH (3/3) 27 pediatric BL, 3 HIV+ from Buenos Aires, Argentina. 
Argentina [15] PBL 4 cases ISH, IHC 100% (4/4) 4 PBL in HIV+ patients from Buenos Aires, Argentina. 
Argentina [16] B-NHL (ped) Cohort ISH 
40% (16/40) (35% BL; 47% 
DLBCL) 
23 BL ped, 17 DLBCL ped from Buenos Aires, Argentina. 




1 PBL in HIV+ from Buenos Aires, Argentina. 




1 PBL in HIV+ from Buenos Aires, Argentina. 
Argentina [19] T-NHL (ped) Cohort ISH, IHC 8% (2/25) 
16 lymphoblastic, 8 anaplastic, 1 hepatoesplenic T-cell lymphoma ped from 
Buenos Aires, Argentina. 
Argentina/Brazil [20] HL (ped) Cohort ISH, IHC 
54% (Arg; 60/111); 48% (Bra; 
31/65) 
111 HL ped from Buenos Aires, Argentina. 65 HL ped from Rio de Janeiro, 
Brazil. 
Argentina [21] PCNSL 7 cases ISH, PCR 100% (6/6) 7 PCNSL cases HIV+ from Buenos Aires, Argentina. 
Argentina [22] HL (ad, ped) Cohort ISH 55% ped (51/92); 31% ad (25/81) 92 HL ped, 81 HL ad from Buenos Aires, Argentina. 
Argentina [23] HIV+ HL, BL, DLBCL 4 cases ISH, IHC 100% (4/4) 1 HL, 2 BL, 1 DLBCL ped HIV+ from Buenos Aires, Argentina. 
Argentina [24] BL (ped) Cohort ISH, PCR 47% (8/17) 17 BL ped from Buenos Aires, Argentina. 
Argentina [25–27] HL (ped) Cohort ISH 51% (22/41) 41 HL ped from Buenos Aires, Argentina. 
Argentina [28] BL (ped) Cohort ISH 25% (4/16) 16 BL ped from La Plata, Argentina. 
Brazil [29] DLBCL Cohort ISH 30% (28/93) 93 DLBCL ad from Sao Paulo, Brazil. 




1 NK/NKL from Rio Janeiro, Brazil. 




1 HVL- LD from Dom Eliseu City, Pará, Brazil. 
Brazil [32] 
HL (ad/ped, temporal 
series) 
Cohort ISH 87–46% (817) 
155 HL ped, 662 HL ad from Sao Paulo, Brazil. 
Brazil [33] 





1 int BL DLBCL from Recife, Brazil. 
Brazil [34] DLBCL (>50 yo) Cohort ISH 8.45% (6/71) 71 DLBCL ad from Sao Paulo, Brazil. 




T/NKL HIV+ from Sao Paulo, Brazil. 
Brazil [36] BL (ped) Cohort ISH 100% (7/7) 4 BL ped, 3 BL ad from Amazonas, Brazil. 
Brazil [37] BL (ped) Cohort ISH 54.1% (33/61) 61 BL ped from Rio de Janeiro, Brazil. 
Brazil [38] HL (ad, ped) Cohort ISH 43% (56/130) 130 HL from Sao Paulo, Brazil. 
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1 HVL-LD from Manaus Amazonas, Brazil. 
Brazil [40] DLBCL, Palatine tonsil Cohort ISH 0% (0/26) 26 DLBCL from Bahia, Brazil. 
Brazil [41–43] HL (ped) Cohort ISH 44.8% (43/96) 96 HL ped from Rio de Janeiro, Brazil. 
Brazil [44,45] HL (ad) Cohort ISH 52.6% (51/97) 97 HL ad from Sao Paulo, Brazil. 
Brazil [46] ENKTCL (ad, ped) Cohort ISH, PCR 100% (74/74) 74 ENKTCL from Sao Paulo, Brazil. 
Brazil [47] HL (ad) Cohort ISH 22% (5/23) 23 HL ad from Sao Paulo, Brazil. 
Brazil [48] CNS DLBCL (ad) Cohort ISH 5.5% total (2/36) (40% IS) 36 CNS DLBCL from Sao Paulo, Brazil. 
Brazil [49] HL (stomach) 5 cases ISH 80% (4/5) 5 HL from Sao Paulo, Brazil. 
Brazil [50] B-NHL (ped) Cohort ISH, qPCR 23% (7/30) 30 NHL ped from Rio de Janeiro and Sao Paulo, Brazil. 




HL PTL from Sao Paulo, Brazil. 
Brazil [52] HL (ad, ped) Cohort ISH, IHC 50.3% (85/169) 169 HL from Sao Paulo, Brazil. 
Brazil [53,54] BL (ad, ped) Cohort ISH 52.6 % (123/234) 
North Region(n = 17 cases), Central West Region(n = 17 cases), Northeast 
Region(n = 86 cases), Southeast Region(n = 72 cases), South Region(n = 42 
cases) 
Brazil [55] BL (ped) Cohort ISH 66% (33/50) 143 pediatricos y 88 adultos, 3 sin edad). 
Brazil [56] BL (ped) Cohort ISH 61% (33/54) San pablo 
Brazil [57] PBL 11 cases ISH, PCR 100% (11/11) Rio de janeiro 
Brazil [58] HL (ad, ped) Cohort ISH, IHC 48% (22/46) San pablo 
Brazil [59] PCNSL 10 cases IHC 10% (1/10) Florianopolis, South of Brazil 
Brazil [60] HL (ad) Cohort IHC, PCR 
37% (11/30); 43% Circulating 
EBV 
14 patients <15 years y 32 >15 years 
Brazil [61] HL (ped) Cohort ISH 86.7% (78/90) Niterói RJ 
Brazil [62–64] B-NHL (ped) Cohort ISH, PCR 72% (21/29) 29 NHL from Rio de Janeiro, Brazil. 
Brazil [65] HL (ad) Cohort ISH, IHC 75.6% (28/37) 37 HL ad from Ceara, Brazil. 
Brazil [66] HL (ad) Cohort IHC 45.8% (38/83) 83 HL ad from Rio de Janeiro, Brazil. 
Brazil [67] HL (ad, ped) Cohort IHC 55% (35/64) 64 HL ad from Rio de Janeiro, Brazil. 
Brazil [68,69] HL (ad) Cohort ISH, IHC 64.1% (50/78) 78 HL ad from Rio de Janeiro, Brazil. 
Brazil [70] HL (ad, ped) Cohort ISH 63.5% (61/96) 96 HL from Sao Paulo and Ceara, Brazil. 
Brazil [71] ENKTCL Cohort ISH 100% (16/16) 16 ENKTCL from Sao Paulo, Brazil. 
Brazil [72] BL (ped) Cohort ISH 73% (8/11) 11 BL ped from Recife, Brazil. 
Brazil [73] HL (ped) Cohort ISH 57.7% (15/26) 26 HL ped from Curitiba, Brazil. 
Brazil [74] BL (ped) Cohort ISH 87% (47/54) 54 BL ped from Bahia, Brazil. 
Brazil [75] BL Cohort ISH 71% (17/24) 24 BL from Sao Paulo, Brazil. 
Brazil [76] HL (ped) Cohort ISH 72% (18/25) 25 HL ped from Sao Paulo, Brazil. 
Mexico [77] HVL-LD Cohort ISH 100% (20/20) 20 HVL-LD ped from Mexico City, Mexico. 
Mexico [78] HL (ad, ped) Cohort ISH 
76.1% ped (22/42); 66.6% ad 
(16/24) 
42 HL ped, 24 HL ad from Mexico City, Mexico. 




1 PCL from Mexico City, Mexico. 
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Mexico [80] PBL 5 cases PCR 80% (4/5) 5 PBL ad HIV+ from Mexico City, Mexico. 
Mexico [81] DLBCL (>50 yrs) Cohort ISH 7% (9/136) 136 DLBCL ad from Mexico City, Mexico. 
Mexico [82] HL (mostly ad) Cohort ISH, IHC 61.4% (35/57) 54 HL ad, 3 HL ped from Mexico City, Mexico. 
Mexico [83] ENKTCL Cohort ISH 96% (22/23) 23 ENKTCL from Mexico City, Mexico. 
Mexico/Bolivia [84] HVL-LD /ACTCLC 4 cases ISH 75% (3/4) 4 ACTCLC ped from Mexico City and La Paz 
Mexico [85] PTLD 8 cases ISH 100% (8/8) 8 PTLD ad from Mexico City, Mexico. 
Mexico [86] NHL, Intestinal Cohort ISH 63% (12/19) 7 T, 6 high grade B, 6 low grade B-NHLs from Mexico City, Mexico. 
Mexico [87,88] HL (ad) Cohort IHC 70% (35/50) 50 HL ad from Mexico City, Mexico. 
Mexico [89] HL (ad, ped) Cohort ISH, IHC 67% (18/27) 3 HL ped, 24 HL ad from Mexico City, Mexico. 
PR [90] HL & NHL (ad, ped) Cohort IHC 
50% HL (11/22); 35% NHL 
(22/63) 
22 HL, 63 NHL from San Juan de Puerto Rico, Puerto Rico. 
DR [91] HL (ped) Cohort IHC 64.3% (18/28) 28 HL ped from Santiago, Dominican Republic 




EBV prevalence in 7 BL ped from La Habana, Cuba. 
Colombia [93,94] HL (ad, ped) Cohort ISH, IHC 
67% (45/67) 60.4% ad; 84.2% 
ped 
48 HL ad, 19 HL ped from Bogotá, Colombia 
Peru [95] DLBCL (ad) Cohort ISH 28% (33/117) 117 DLBCL ad from Lima and Arequipa, Peru. 
Peru [96] 





LBCL ad from Lima, Peru. 
Peru [97] HVL-LD 4 cases ISH 100% (3/3) 4 HVL-LD ped from Lima, Peru. 
Peru [98] EBV+ DLBCL GI (ad) 5 cases ISH 100% (5/5) 5 DLBCL GI ad from Lima, Peru. 
Peru [99] Systemic T/NKL 6 cases ISH, IHC 100% (6/6) 6 T/NKL ped from Lima, Peru. 
Peru [100,101] EBV+ DLBCL (>50 yo) Cohort ISH 14% (28/199) 199 DLBCL ad from Lima, Peru. 








Cohort ISH 100% (15/15) 
12 T/NKL ped, 2 T/NKL ad from Lima, Peru. 
Peru [104] ENKTCL Cohort PCR 99% (76/77) 77 ENKTCL from Lima, Peru. 
Peru [105] HVL-LD 6 cases ISH 100% (6/6) 6 HVL-LD ped from Lima, Peru. 
Peru [106] ENKTCL Cohort ISH, IHC 96% (27/28) 28 ENKTCL ad from Lima, Peru. 
Peru [107] Nasal lymphoma Cohort ISH 93% (14/13; 11/11 T-cell) 13 Nasal lymphoma from Lima, Peru. 
Peru [108] HL (mostly ped) Cohort ISH, IHC 94% (30/32) 32 HL from Lima, Peru. 
Ecuador [109] HVL-LD 2 cases ISH 100% 1 HVL-LD ped, 1 HVL-LD ad from Quito, Ecuador. 
Ecuador [110] HL and NHL (ad) Cohort ISH, qPCR 
55.5% HL (5/9); 59.5% NHL 
(25/42) 
9 HL ad, 42 NHL ad from Guayaquil, Ecuador. 






DLBCL from Santiago, Chile. 
Chile [112] Nasal lymphoma Cohort ISH 
DLCBL 0% (0/3); T-cell 0% 
(0/1); NKT 100% (6/6) 
3 DLBCL, 1 T-cell lymphoma, 6 NKT from Valdivia, Chile. 
Chile [113] ENKTCL Cohort ISH 78% (7/9) 9 ENKTCL ad from Santiago, Chile. 




BL (mostly ped) Cohort ISH 
41% (7/17 Arg); 50% (5/10 
Chile); 58% (7/12 Br) 
37 BL ped, 2 BL ad from Buenos Aires, Argentina; Santiago, Chile; Campinas, 
Brazil. 
Honduras [115] HL (ped) Cohort ISH 100% (11/11) 11 HL ped from Tegucigalpa, Honduras. 
CR [116] HL (ad, ped) Cohort IHC 40% (16/40) 6 HL ped, 34 HL ad from San Jose, Costa Rica. 
CR [117] HL (ped) Cohort ISH, IHC 81% (34/42) 42 HL from San José, Costa Rica. 
CR/Mexico [118] HL (ad, >15 yo) Cohort ISH, SB 
36% (5/14) CR; 77% (24/31) 
Mexico 
45 HL ad from Mexico City, Mexico; San Jose, Costa Rica. 
Bolivia [119] NHL 8 cases ISH 75% (6/8) 8 NHL from Santa Cruz, Bolivia. 
Guatemala [120] ENKTCL Cohort ISH 87% (73/84) 59 ENKTCL from Guatemala City, Guatemala. 
ACTCLC: angiocentric cutaneous T-cell lymphomas of childhood; B-NHL: B-cell non-Hodgkin lymphoma; CNS: central nervous system; CSF: cerebrospinal fluid; 
DLBCL: diffuse large B cell lymphoma; GI, gastrointestinal; HL, Hodgkin lymphoma; HVL-LD: hydroa vacciniform-like lymphoproliferative disease; IC: 
immunocompetent; IHC: immunohistochemistry; IS: immunosuppressed; ISH: Epstein–Barr virus-encoded small RNAs (EBERs) in situ hybridization; ENKTCL: 
extranodal nasal-type T-cell/NK lymphoma, PBL: plasmablastic lymphoma; PCL: plasma cell myeloma; PCNSL: primary central nervous system lymphoma; PTL: 
peripheral T cell lymphoma; qPCR: quantitative real-time PCR; SB: Southern blot; T-NHL: T-cell Non-Hodgkin Lymphoma; Pt: patient; ad: adult; ped: pediatric. 
Countries PR, DR and CR: Puerto Rico, Dominican Republic and Costa Rica. virus+ refers to virus positive samples. 
Cancers 2020, 12, 2166 8 of 58 
 
2.1. EBV-Associated Lymphoid Neoplasms in Latin America 
2.1.1. Hodgkin Lymphoma 
There are several series of lymphomas reported in this region, particularly at the end of last 
century, which, however, were only classified as Hodgkin and non-Hodgkin (NHL), and which 
obviously did not follow the latest WHO classification. HL has a bimodal age distribution, there is an 
early peak occurring in adolescents and young adults, and a late peak after 50 years of age in 
industrialized countries. Developing countries also exhibit a bimodal distribution of the disease, but 
the early peak starts before adolescence [121]. In the US, pediatric HL shows the highest incidence in 
adolescents between 15–19 years of age, while developing countries present similar incidences than 
the US for adolescents, but also exhibit a marked augmented incidence in young children [122,123]. 
In developing countries, classical HL (cHL) with an early onset (14 yrs or younger) shows high EBV 
association, more often of the mixed cellularity (HL-MC) subtype. A strong male to female 
predominance is also observed, particularly in the group younger than 5 yrs, in which the ratio is 5:1. 
HL in adolescents and young adults displays lower EBV association, nodular sclerosis subtype (HL-
NS) predominance and affects male and females almost equally [122]. 
We found 36 studies of HL in LA, including pediatric and adult series from 12 countries. 
Pediatric series from Argentina exhibited a profile compatible with early cHL (i.e., younger ages, EBV 
positivity of ~50% and HL-MC as the predominant subtype) [20,25–27], while adult HL displayed a 
31% of EBV-association, with similar frequencies of both NS and MC subtypes [22]. On the other 
hand, in the Southeast of Brazil, EBV positivity was 40–50%, HL-NS was the predominant subtype, 
and there was a smooth peak between adolescents and young adults [38,41–45,47,52,58,60,66–70,73], 
which may suggest a transition state in the epidemiology of the disease presentation between the 
ones observed in developing and developed areas. Indeed, one study in the most affluent Brazilian 
State (Sao Paulo) reviewed 817 cases of cHL over 54 years (1954–2008), describing that EBV-positive 
cases showed a decrease from 87% to 46% during the time of the study, with a remarkable decrease 
in young adults (85% to 32%) [32]. Nevertheless, HL-NS was still the predominant subtype in all 
periods. On the contrary, HL in the North of Brazil exhibits high EBV association (87%), HL-MC and 
young age predominance [61]. These results support the hypothesis that the socioeconomic level may 
determine the presentation features of this neoplasm, also highlighting the role of EBV as an HL 
driver that is also influenced by socioeconomic factors. Figure 1A–D shows examples of EBV positive 
HL-NS and HL-MC. 
There is only one large pediatric cohort of 42 cases published from Mexico, with a median age 
of 5 yrs at diagnosis, and in which a male predominance (2.5:1) was observed [78]. EBV positivity 
was found in 76.1% of the cases and the HL-MC subtype was the most predominant (71.4%). Other 
studies from Mexico mostly include young and older adults, with scarce inclusion of children and 
adolescents, and in which EBV association frequencies vary between 61% and 77%. In those studies, 
a predominance of HL-MC and HL-NS subtypes was observed [82,87–89,118]. In these Mexican 
studies, a high EBV association was also observed for the lymphocyte depleted (HL-LD) subtype, 
with 91.2% positive cases [87–89]. 
In line with the above-described data, a 94% of EBV association was observed in pediatric HL in 
Peru [108], while in Colombia, EBV association varied from 60% in adults to 84% in children [93,94]. 
Another study from Honduras that included 11 children younger than 15 yo also found 100% EBV 
positivity [115]. Series of studies from the Caribbean and continental Central American countries: 
Puerto Rico, Ecuador, Costa Rica and the Dominican Republic found intermediate EBV association 
frequencies (50%, 55%, 36–40% and 64%, respectively) [90,91,110,116–118], which are closer to the 
frequencies observed in the more developed Argentina. These frequencies should be confirmed with 
more samples and up-to-date techniques. 
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Figure 1. Hodgkin lymphoma. (A–C). Nodular sclerosis Hodgkin lymphoma. (A). Hematoxylin-Eosin 
staining. (B). CD30 staining with arrows pointing at positive Reed-Sternberg cells. (C). Epstein–Barr 
virus-encoded small RNAs (EBER) in situ hybridization. (D). EBER in situ hybridization of a mixed 
cellularity Hodgkin lymphoma, magnification 40×. (E,F). Diffuse large B cell lymphoma, 
magnification 40×. (E). CD30 staining. (F). LMP1 (latent membrane protein 1) staining. 
2.1.2. Burkitt Lymphoma 
BL is a highly aggressive B cell lymphoma, characterized by the translocation of the MYC 
oncogene to the immunoglobulin loci. It affects mostly children and is also more predominant in 
males [124]. EBV-associated BL conforms almost 100% of endemic BL and around 20% of sporadic 
cases of North America and Europe. Other regions of the world, especially developing populations, 
exhibit intermediate frequencies, such as 50–70% in North Africa and Russia [3,125]. Pediatric BL in 
Argentina has an EBV association frequency closer to the sporadic subtype (25–47%), and the highest 
incidence of EBV-positive cases is in children younger than 5 yo [14,16,24,28]. As with HL, the 
frequency of EBV positive cases increase with latitude in Brazil, being ~60% in the South East 
[37,55,56,62–64], and 73–87% in North East [72,74]. A study including an extensive number of BL 
cases from five Brazilian geographic regions confirmed this trend, disclosing EBV association 
frequencies from 29% in the South to 76% in the North [53,54]. This pattern appears to represent a 
socio-geographic gradient, which might reflect social development, as well as other unknown 
environmental, ethnic or genetic factors [63]. A Brazilian study of 14 population-based cancer 
registries showed that the global age-adjusted incidence rate for pediatric BL does not differ 
significantly from the expected for a sporadic BL region. However, the incidence was elevated for BL 
children aged 1–4 years [126]. Given the association of EBV positive BL with young age, it is tempting 
to ascribe this elevated risk to the early EBV seroconversion, which is characteristic of the natural 
history of EBV infection in our geographic region [127]. Indeed, an EBV-associated BL inverse 
correlation with age has been shown in other studies from Brazil [56] and Argentina [14]. 
Unfortunately, we could not find reports on BL series from the Andean and Caribbean regions of LA, 
which, most probably, does not represent a low frequency of this lymphoma there. Although there 
are studies including BL from Mexico, they do not address EBV infection, and there is only one case 
report from a 63 yo male with an EBV positive intraoral BL [128]. 
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2.1.3. Diffuse Large B Cell Lymphoma 
DLBCL is a highly aggressive neoplasm that can arise in almost any location of the body. It is 
very rare in pediatric patients and young adults, but is one of the most common NHLs in older 
individuals. Due to the median age of presentation of 70 yrs, it is usually associated with underlying 
immunosuppression. In the former 2008 WHO classification [129], EBV-positive DLBCL of the elderly 
(>50 years) was recognized as a provisional entity among the DLBCL subtypes. This provisional 
entity represented 5–11% of the DLBCL among immunocompetent East Asian patients [130], while 
in Western populations, the frequency was lower than 5% [81,131]. The reported series from LA have 
shown slightly higher EBV association frequencies (7% México, 9% Brazil, 13% Argentina and 14–
28% Peru) [10–12,34,81,95,100,101] than the observed in Western countries [81]. LA patients are also 
younger than the ones described in other series [11,81]. Peru is particularly interesting, since it has 
the highest incidence of positive EBV DLBCLs, in addition to the incidence of DLBCL being the 
highest reported, accounting for up to 45% of all lymphomas [100,101,132]. In a Peruvian study of 
five cases, DLBCL of the gastrointestinal tract was consistently associated with EBV infection in 
elderly patients [98]. Remarkably, a series of cases of DLBCL of the palatine tonsils from Salvador de 
Bahia Brazil did not find an association with EBV [40]. Figure 1E,F shows an example of an EBV 
positive DLBCL. 
In the 2016 WHO classification of lymphoid neoplasms, the age factor was eliminated from the 
association of EBV with DLBCL, leading to the substitution of the modifier “elderly” with “not 
otherwise specified” (EBV-positive DLBCL, NOS) [9]. Therefore, new studies free from the restraint 
of the age limit are needed, to better characterize the magnitude of this association, as well as the 
prognostic impact of EBV positivity in LA patients. DLBCL are also distinguished by their phenotype 
as germinal center or activated, with the former exhibiting an overall better survival rate. No 
differences were found in a series of Argentinian cases with respect to EBV positivity in these two 
subtypes of DLBCL [11,95]. 
2.1.4. T and NK Lymphoproliferative Disorders 
Although EBV tropism is mainly of B cells and in healthy individuals exclusively localizes in B cells 
[133], the revised 2016 WHO classification recognizes the chronic active EBV infection (CAEBV) of T/NK 
cell type, the aggressive NK-cell leukemia, the systemic T-cell lymphoma of childhood and the extranodal 
NK/T-cell lymphoma, nasal type (ENKTCL), as well as a new provisional entity, the primary EBV-positive 
nodal T/NK-cell lymphoma [9,134]. These neoplasms represent a broad spectrum of diseases that occur 
with higher incidence in Asian populations, and, in which, CAEBV, the aggressive NK leukemia and the 
systemic T-cell lymphoma are more prevalent in children and adolescents, while ENKTCL mainly affects 
adults [9,134]. How the virus infects T or NK cells is still a matter of debate, but exists some evidence of a 
preferential tropism for T cells for the EBV-2 subtype [135,136]. 
CAEBV corresponds to a group of reactive LPDs associated with a heightened EBV infection 
lasting longer than IM, and with the potential to progress to a systemic lymphoma. The clinical 
picture is diverse and includes the indolent, localized cutaneous form hydroa vacciniform-like LPD 
(HVL-LPD), renamed by the revised 2016 WHO classification [9]. Several series of patients with HVL-
LPD have been described in LA indicating a high incidence of this disease, mainly in countries with 
a large Amerindian population component, such as Mexico [77,84], Bolivia [84], Peru [97,103,105] and 
Ecuador [109]. In Brazil, two HVL-LPD cases were reported in children from Amazon indigenous 
tribes, supporting the ethnic bias of this disease [31,39]. In these series of patients, the association 
with EBV was virtually 100%. These studies have also greatly contributed to illustrate the clinical and 
pathological features of this disease in LA as an LPD with 70% of cases being of T-cell origin and 30% 
of NK origin. This scenario is more similar to Asian CAEBV, since, in the US, CAEBV is very rare, 
and also presents as a B cell LPD [137]. Although cellular and viral monoclonality has been proven 
in the majority of T-cell cases, the disease is today considered an LPD, with a high risk to progress 
into a systemic lymphoma [77], to reflect the diverse clinical spectrum of the disease presentation, 
from self-limited HV to HV-like lymphoma, and also to allow for more adequate therapeutic 
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approaches, since patients respond well to immunomodulatory agents as first line of treatment 
[77,103,105]. 
Extranodal NK/T cell lymphoma (ENKTCL) is an EBV-positive lymphoma more commonly 
derived from NK cells. Similar to CAEBV lymphoproliferations, this type of lymphoma has been 
described mainly in East Asia and LA, in which the ethnic composition includes a high proportion of 
Amerindians. EBV infection is also confirmed in virtually all cases. Series of cases have been reported 
from México [83], Peru [104,106], Chile [104,106,112,113] and Guatemala [120]. In Brazil, ENKTCL 
usually occurs as isolated cases [71]. Recently, a large series was reported that included 122 cases 
with mostly adults (only three children) from all five Brazilian regions [46]. In this Brazilian cohort, 
the clinico-pathological characteristics of the neoplasm were similar to the ones described in patients 
from East Asia and other American countries, in which the disease is considered endemic. No ethnic 
data was recorded for the patients included in the study. In a Brazilian unicentric study that included 
lymphomas involving the midline facial region, 16 were of T/NK cell origin and nine were of B cell 
origin (n = 25). Remarkably, no ethnic differences were found between the patients with T/NK or B 
cell presentation [71]. Figure 2 shows an example of an ENKTCL. 
 
Figure 2. Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL). (A). Hematoxylin-
Eosin staining. (B). CD56 staining. (C). CD3 staining. (D). EBER in situ hybridization. 
3. Kaposi Sarcoma Human Herpesvirus 
KSHV is a gamma-2 herpesvirus closely related to EBV, also called human herpesvirus 8 or 
HHV8. KSHV is the etiological agent of Kaposi sarcoma (KS), multicentric Castleman disease (MCD) 
and primary effusion lymphoma (PEL). The revised WHO classification of hematopoietic and 
lymphoid tissues also included two entities associated with KSHV, the HHV8-positive diffuse large 
B-cell lymphoma, NOS and the HHV8-positive germinotropic lymphoproliferative disorder. KSHV-
associated neoplasms usually develop in severely immunocompromised patients, and, as such, KS 
is, in many countries, an AIDS defining marker. The incidence of KS has sharply diminished after the 
introduction of anti-retroviral therapy, but has since stabilized in many countries [138]. In regions in 
which the virus is endemic, such as in Sub-Saharan Africa, HIV negative KS (classic KS or cKS) is one 
of the most common neoplasms in men [139]. 
MCD and PEL are extremely rare neoplasms. There are two main presentations of Castleman 
disease (CD), one in which reactive B cells only affect a single group of close lymph nodes, denoted 
as unicentric (UCD) and MCD, in which more than one group of lymph nodes are reactive. CD is also 
classified according to its microscopic morphology as hyaline-vascular (usually UCD), and plasma 
cell and plasmablastic (usually MCD). CD is not a true lymphoma, but rather a polyclonal B cell 
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expansion and is thus considered an LPD. MCD is associated with HIV and KSHV co-infection, and 
if HIV is uncontrolled, MCD can have an aggressive clinical course and progress to an entity with 
cellular and viral monoclonality, in which it resembles a DLBCL [140]. On the contrary, PEL is an 
aggressive monoclonal B cell lymphoma with a poor clinical outcome, regardless of a down the line 
HIV control. PEL usually presents with lymphoid effusions in cavities, such as the pleura, peritoneum 
and pericardium. Post-transplant LPD and germinotropic LPD are also very rare and recently 
recognized [141,142], therefore, we could not find studies about them. Of interest is that in about 80% 
of PELs arising in AIDS patients, the tumor cells are co-infected with KSHV and EBV, a characteristic 
in common with germinotropic LPD [140]. 
KSHV Prevalence and Morbidity in Latin America 
To our knowledge, there is no routine screening for KSHV infection in blood banks in LA countries, 
nor in the rest of the world, and the World Health Organization and the World Federation of Hemophilia 
do not recommend it [143]. Thus, one problem when assessing the incidence of KSHV infection is that 
there is not a reference standard assay, and comparative studies have often demonstrated great disparity 
[144]. Therefore, comparing different studies may be inaccurate. Blood donor-based studies from Brazil 
illustrate this point (see Table 2), while some studies from Sao Paulo report a prevalence of 3.8–4.6% [145–
147], another found 26% [148]; albeit, 1.1% positives were found among health workers and 20.4% in 
HIV/AIDS patients from the same city [149]. A screening of blood donors from the Amazonian region also 
found a high prevalence of 31.3% [150]. Pediatric studies found 7.6% positivity in Sao Paulo, 6.8% in 
Campinas and 12% in children of low-income families from Belem Pará [151–153]. Figure 3 summarizes 
studies about the KSHV prevalence among LA countries. 
 
Figure 3. Kaposi sarcoma herpesvirus (KSHV) prevalence. Numeric values are in percentage. ND: not 
determined. 
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Methods Results Description of the Study 
Brazil 
[148] 
Prevalence EIA, IFA 25.1% KSHV+ 
Screening of blood donors from Sao Paolo, Salvador and Manaos (February–
December 2003). n = 3493 
Brazil 
[150] 
Prevalence EIA, IFA 31.3% KSHV+ 
Screening of non-Amerindians blood donors from Mapuera and Manaos 
(Amazon). n = 1120 
Brazil 
[149] 
Prevalence IFA 1.1% KSHV+ health care workers 




Prevalence EIA, IFA 4.6% KSHV+ 
Screening of blood donors from Vitoria and Sao Paolo (January 1998–April 
1999). n = 747 
Brazil 
[153] 
Prevalence EIA 16.3% KSHV+ 
Screening of 81 low-income families from Belem Para, derived from a 
previous rotavirus study. n = 467 
Brazil 
[145] 
Prevalence IFA 4% KSHV+ Screening of blood donors from Sao Paolo. n = 400 
Brazil 
[146] 
Prevalence IFA 3.8% KSHV+ Screening of blood donors from Sao Paolo (2000–2002). n = 319 
Brazil 
[152] 
Prevalence ISH 6.83% KSHV+ 
Screening of children (0–20 yo) from Campinas after removal of either/both 
tonsil or adenoids. n = 293 
Brazil 
[151] 
Prevalence IFA, WB 9.35% KSHV+ Screening of children (0–12 yo) from Rio de Janeiro. n = 171 
Brazil 
[154] 
Case report IFA 
40 yo female with UCD hyaline variety; 62 yo with MCD mixed hyaline and 
plasma cell. Patients died, because of progression to NHL 






41 yo male with KSHV+ MCD co-presented with KS. 35 yo male had no 
KSHV test 
Description of two HIV/AIDS patients with MCD plasma cell variant 
Brazil 
[156] 
Case report IHC 32 yo male with MCD plasmablastic variant 




Case report IHC 40 yo male with MCD plasmablastic variant Description of an HIV/AIDS patient with MCD co-existing with KS 
Brazil 
[158] 
Case report Histology 37 yo male with MCD. No KSHV or HIV test Description of a patient with MCD plasma cell variant 
Brazil 
[159] 
Case report PCR 44 yo male with PEL Description of an HIV/AIDS patient 
Brazil 
[160] 
CSS PCR One (2%) bone marrow sample was KSHV+ Screening of patients with multiple myeloma. n = 48 
Arg [146] Prevalence IFA 3.6% KSHV+ 
Screening of blood donors from Buenos Aires, Bahia Blanca and Cordoba 
(January 2000–December 2002). n = 1,859 
Arg [161] Prevalence PCR 6.6% KSHV+ 
Screening of blood donors from Buenos Aires and San Salvador de Jujuy. n = 
772 
Arg [162] Prevalence EIA 7.8% KSHV+ Screening of blood donors from Buenos Aires. n = 577 
Arg [163] Prevalence EIA 6.4% KSHV+ 
Screening of repository samples from a previous cervical cancer study from 9 
countries. Concordia Argentina. n = 968 
Arg [164] CSS PCR One KSHV+ Description of DLBCLs in HIV+ patients. n = 11 
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Arg [165] Case report IFA, PCR 
36 yo male with MCD hyaline vascular. 49 yo male MCD plasmablastic co-
presenting with KS. 
Report of two cases of KSHV+ MCD in HIV+ patients 
Arg [13] Case report PCR 34 yo male with DLBCL EBV+ and KSHV+ Description of a DLBCL in an HIV/AIDS patient 






I MCD and 1 PEL are described KSHV genotyping 
Col [163] Prevalence EIA 13.32% KSHV+ 
Screening of repository samples from a previous cervical cancer study from 9 
countries. n= 1883 from Colombia (Bogota City) 
Chile 
[146] 
Prevalence IFA 2.6% KSHV+ Screening of blood donors from Santiago (2000–2002). n = 300 
Peru 
[168] 




Two UCD hyaline variety are reported as KSHV+. One MCD plasma cell was 
KSHV negative. 
Description of CD patients from two hospitals in Lima. n = 10 
Mex [170] CSS IHC Only one neoplasm was a KSHV+ MCD Description of CD patients from a Mexico City hospital (2000–2015). n = 39 
Mex [171] CSS Histology 5 MCDs are found but no test for KSHV infection 
Description of CD patients from a Mexico City hospital between 1996–2003. n 
= 11. 
Mex [172] CSS Histology 1 (4.8%) PEL 
Analysis of malignant neoplasms in HIV+ patients from a Mexico City 
hospital (January 2005–July 2008). n = 21 
Mex [173] Case report IHC 73 yo HIV- female. EBV- lymphoma Description of CD coexisting with a DLBCL. 
Mex [174] Case report IHC 36 yo HIV+ male 
Description of a KS coexisting with a plasmablastic lymphoma and previous 
history of CD. 
PR [175] CSS Histology 
4.8% developed neoplasia, Lymphomas are reported but are not classified 
further 
HIV+ patients from a Bayamon Institute. n = 3576 
Cuba 
[176] 






2 PEL patients are included. No association is found between specific KSHV 
strains and any disease. 
Molecular classification of KSHV strains isolated from KS patients, lymph 
node lesions and contacts of KS patients. n = 90 
Cuba 
[178] 
Prevalence IF 16.9% KSHV+ Screening of archival samples from a previous oral cancer study. n = 379 
Cuba 
[179] 
Case report Histology 
4 cases hyaline-vascular histological variety and 1 case to plasmacellular 
variety. 
Description of five cases of CD 
CR [163] Prevalence EIA 9.81% KSHV+ 
Screening of repository samples from a previous cervical cancer study from 9 
countries. n= 1008 from Costa Rica (Guanacaste province) 
CD: Castleman disease; CSS: cross sectional study; DLBCL: diffuse large B-cell lymphoma; EIA: enzyme linked immunoassay; HIV/AIDS: human immunodeficiency 
virus/acquired immunodeficiency syndrome; IF: immunofluorescence; IH: immunohistochemistry; KS: Kaposi sarcoma; MCD: multicentric Castleman disease; PA: 
particle agglutination; PEL: primary effusion lymphoma; RIPA: radioimmunoprecipitation; SB: Southern blot; Seq: sequencing; UCD: unicentric Castleman disease; 
WB: western blot, virus+ or virus- refers to virus positive or virus negative samples. 
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Argentina reports a prevalence of 3.6–7.4% [146,161–163], higher for San Salvador Jujuy in the 
North West of the country (12.3%), a region with a high population of immigrants and indigenous 
[161]. Higher prevalence for females than males was reported in two Brazilian studies, one pediatric 
(14.9:1) and one adult (3.7:1) [145,151], while in San Salvador Jujuy, the opposite was observed, with 
a male to female ratio of 3:1. More limited studies from Colombia (n = 25), Chile (n = 300) and Peru (n 
= 128) found 4%, 2.6% and 56.2% positivity, respectively [146,168,180]. In Peru, high endemicity was 
also challenged by a different study, in which the MSM high risk group was analyzed (n = 497), 
finding a seropositivity of 42.4% [181]. However, Peru is among the few countries from LA with 
multiple reports of cKS [182,183], including a large cohort of 126 cases that included pediatric cKS 
[184]. There are not large prevalence studies from Mexico, Central America and the Caribbean 
countries, a small screening of blood donors from Cuba (n = 171) found 1.2% KSHV positives [176]. 
Mexico reports KS as the most common neoplasm in AIDS patients, particularly before HAART 
[185,186]. For KSHV studies based on risk groups, see Table 3. 
Table 3. KSHV in risk groups. 
Country 
(Ref) 
KSHV Prevalence Risk Groups 
HIV+ FSW Oral Cancer Patients Close Contacts MSM 
Cuba [176,187] 
20.8% 
n = 154 
 
33.5% 
n = 191 
46.1–72.7% 
X = 62.9% 




X = 21.8% 
n = 2358 
6.7% 
n = 90 
   
Honduras [193] 
31.8% 
n = 22 
9.4% 
n = 96 
   
Colombia [180] 
8% 
n = 25 
    
Peru [181] 
66.5% 
n = 197 
   
26.7% 
n = 300 
Argentina [194] 
17.4% 
n = 144 
    
Prevalence of KSHV infection in specific risk groups, percentages and the number of tested 
individuals (n) are given. When more than one study was found, the range of positives and the 
average (X) are also given. FSW: female sex workers, MSM: men that have sex with men. 
LA harbors distinct ethnic groups differentially distributed among different geographic regions 
in each country. Most urban populations are formed by mestizos and a minority of Caucasians, while 
some rural regions concentrate pure Amerindians or Afro-descendants. KSHV hyper endemicity is 
reported among LA indigenous populations and a hyper-endemicity area (30–100% prevalence) is 
reported among tribes inhabiting the South American lowlands of the Amazonas and the savannah 
(Figure 4 maps the prevalence of KSHV among Amerindian populations). For instance, Amazonian 
Amerindians from Ecuador were found 24% (the Siona, n = 41) to 100% (the Huaorani, n = 38) 
seropositive [195], while in Brazil different studies have found 56.8–79.1% among Amerindians from 
the Pará state (n = 339–1270) [150,196–198] and 50–83% (n = 110) among Amerindian tribes from 
transitional zones in central Brazil from Amazonian to the savannah. On the other hand, 0–14% 
positivity has been found in Amerindians from the South of Brazil (n = 85) [198]. Chacó Amerindians 
(n = 55) from Bolivia were 22% positive and 45% were positive in Paraguay [198]. 
Although our main aim was to document the incidence of lymphomas mediated by tumor 
viruses in LA, there are no such studies for KSHV in many LA countries, with most studies being 
about the prevalence of KS in HIV/AIDS patients. Additionally, because many of the reports are from 
the 1980s and 1990s, the studies only addressed the overall frequency of lymphomas, and lymphomas 
were only classified as Burkitt, Hodgkin and non-Hodgkin. Thus, both MCD and PEL seem more 
common after HAART, but they may have been under-diagnosed in early studies. Furthermore, 
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KSHV-associated neoplasms most often are reported based on their histological and clinical 
characteristics, lacking confirmatory tests for viral infection. KSHV-associated lymphomas are 
reported from Brazil, Argentina and Peru. We found five cases of MCD in Brazil, mostly of the 
plasmablastic variety, and one mixed plasmablastic and hyaline [154–158]. Although KSHV infection 
was not assessed in all cases, four cases were in HIV infected individuals and in three cases MCD co-
presented with KS. There was also a case of PEL in an HIV positive patient [159], and a multiple 
myeloma patient with a bone marrow KSHV PCR positive [160]. We found three KSHV positive MCD 
from Argentina, two PEL and two KSHV positive DLBCL, all in HIV positive patients [13,165–167]. 
One of the DLBCL was also positive to EBV infection [164]. On the other hand, a screening of a series 
of cases of B cell lymphomas arising in HIV/AIDS patients (n = 49) did not find any KSHV positive 
supporting the rarity of these kind of neoplasms [199]. Peru reported two cases of UCD hyaline that 
were KSHV positive by IHC [169]. We found only one PEL and three MCD reported from Mexico 
[170,172,173], and two PEL and one MCD from Cuba [179,187]. Figure 5 shows KSHV positive PEL 
and MCD. 
 
Figure 4. KSHV and human T-lymphotropic virus (HTLV) locoregional prevalence among 
Amerindian tribes. 
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Figure 5. KSHV associated lymphomas. (A–D) Primary effusion lymphoma KSHV and EBV positive. 
(A) KSHV LANA (latency-associated nuclear antigen) staining. (B) Lambda light chain staining. (C) 
Kappa light staining. (D) EBER in situ hybridization. (E,F) Multicentric Castleman disease. (E) 
Hematoxylin-Eosin staining. (F) KSHV LANA staining, magnification 40×. 
There are five major KSHV genotypes described (A, B, C, D and E), mainly based on the 
hypervariable regions of the oncogenic K1 gene. Interestingly, in the series of studies from LA, while 
genotypes A, B and C [167,177,190,200–202] were described in neoplasms or HIV positive cases, 
subtype E has been the sole genotype found in Amerindians from Ecuador, Brazil and French Guiana 
[190,195,197,203–205]. Genotypes A and C are prevalent in Europe and North America, while 
genotype B is more prevalent in individuals with African ancestry [195]. Thus, one plausible 
explanation for the low incidence of KSHV-induced neoplasms (including cKS) among South 
American Amerindians is a low oncogenicity of the KSHV genotype E. Indeed, only two KS reported 
in Peru shared genotype E [204], while KSHV A and B genotypes have been isolated from Brazilian 
and Argentinian patients with European ancestry [201,206]. To our knowledge, the tumorigenic 
activity of the genotype E K1 has not been tested in vitro or in animal models, and it is not clear why 
KSHV would become more attenuated in South American Amerindians, but not in other populations 
with an equally prevalent KSHV infection, such as those from Uganda or Zambia. 
4. Human T-Cell Lymphotropic Virus 
HTLV belongs to the family Retroviridae, genus Deltaretrovirus, and, as such, its genome 
consists of two identical copies of positive sense single stranded RNA that during its life cycle is 
converted into double stranded DNA and inserted into the DNA of the human host cell. This 
integrated form is referred to as the provirus, and HTLV predominantly exists in the host as a cell-
associated provirus. Indeed, infected cells hardly produce any virus and plasma viral load is usually 
undetectable. There are two main types of HTLV infecting humans, HTLV-1 that preferentially infects 
CD4+, but also CD8+ T-lymphocytes, and HTLV-2 that preferentially infects CD8+ T-lymphocytes. 
Two other HTLV types have been described in Africa, but today, it is not clear whether HTLV-3 and 
HTLV-4 can be transmitted from human to human or are exclusively zoonotic, and no clinical disease 
has been associated with these two novel isolates thus far [207]. 
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HTLV-1 and -2 are very similar in terms of genome structure and replication patterns, but they 
are strikingly different in terms of clinical impact and geographical distribution. HTLV-1 is present 
throughout the world with regions of high endemicity together with low prevalence in neighboring 
zones. Major endemic regions include Southwest of Japan, LA and some areas of West Africa 
[208,209]. Ten to twenty million people are estimated to be infected with HTLV-1. However, the 
world prevalence of HTLV-1 is largely unknown, since most published studies are performed on 
blood donors and there are not population-based studies. The epidemiology and pathogenic 
potential of HTLV-2 infection are less well characterized. HTLV-2 is present in many world areas, 
and high HTLV-2 seroprevalence has been reported in indigenous populations in Africa and 
Amerindians from Central and South America, as well as among IVDU in Europe and North America 
[209]. Moreover, six genotypes have been found for HTLV-1 based on the genomic sequences of the 
long terminal repeats, A (also called the Cosmopolitan strain, because of its worldwide distribution) 
to G (the rest of them with a somehow more restricted geographical distribution) and five for HTLV-
2, A to E [210]. 
HTLV-1 infection has been associated with adult T cell leukemia/lymphoma (ATLL) and a subacute 
myelopathy known as tropical spastic paraparesis or HTLV-1-associated myelopathy (TSP/HAM). 
Although most HTLV-1 carriers are asymptomatic, about 5% of them will develop clinical complications, 
including TSP/HAM and ATLL. Both diseases are severe and produce progressive incapacitation or 
death. In addition to ATLL and TSP/HAM, infection by HTLV-1 also leads to a broad spectrum of 
inflammatory diseases with significant morbidity, such as uveitis, arthritis, myositis, infective dermatitis, 
Strongyloides stercoralis infection and crusted scabies [209,211]. The mechanisms leading to them are 
currently unknown. On the contrary, and in spite of sharing 60% of genetic homology, no disease has been 
consistently associated with HTLV-2 infection, although sporadic cases of subacute myelopathy or 
hematological malignancies have been reported [209]. 
HTLV Prevalence and Morbidity in Latin America 
When assessing the viral prevalence, we found that the majority of studies are based on 
immunological methods that do not discriminate between HTLV-1 and HTLV-2 (referred to as 
HTLV). The Caribbean basin is usually considered endemic to HTLV infection, perhaps because early 
1980s studies documented several cases of ATLL from black immigrants from the Caribbean islands 
[212,213]. There are several studies from Cuba and Dominican Republic that tried to confirm that 
high endemicity and morbidity. Surprisingly, three sero-epidemiological studies carried on Cuban 
blood donors found 0.25%, 0.27% and 0.99% HTLV positivity, even though they included a significant 
number of black Cubans [214–216]. Dominican Republic and Puerto Rico report 2.5% and 0.2% 
positivity in blood donors, respectively [217–219]. Higher prevalence has been reported for risk 
groups. A retrospective study from 1996 to 2007 from two sentinel hospitals from Havana and 
Matanzas Cuba that registered all lymphoid neoplasms, reported only five ATLL cases [220]. On the 
contrary, in spite of multiple reports about TSP/HAM in Dominican Republic and Puerto Rico 
[218,221–223], we could not find a single ATLL case. Although it is not clear which is the most 
prevalent subtype, HTLV-1 is almost exclusively the one reported [216,220,224,225]. Thus, the low 
incidence of ATLL may be due to the low prevalence of HTLV infection, or the scarcity of other 
needed co-factors. For a summary of data see Table 4. 
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Table 4. Summary of HTLV studies. 




Description of Study 
(Ref) (Main Finding) 
Mexico 
[226] 
Prevalence PA, WB 0.39% HTLV-1/2+ Screening of blood donors from Monterrey. n = 1017 
Mexico 
[227] 
Prevalence EIA 2.8% HTLV+ Screening of emergency room patients from Mexico City. n = 909 
Mexico 
[228] 
Prevalence EIA, PA, WB 0.3% HTLV+ healthy women Screening of healthy women (n = 662) & cervical cancer patients from Yucatan. 
Panama 
[229] 
Prevalence EIA 5% HTLV+ Screening sera from previous studies (meningitis and enterovirus). n = 754 
Panama 
[230] 
Case report EIA, WB HTLV-1+ Description of ATLL patient 
Panama 
[231] 
CSS EIA, IFA, WB, RIPA 
7 cases HTLV+ 
Analysis of hematologic malignancies. n = 136 
3 cases confirmed ATLL 
Hond [232] Prevalence EIA, WB, PCR 
8.1% HTLV-1+ of non- mestizos 
Screening of blood donors from 15 cities of the Atlantic coast (n = 2651) 
0.5% HTLV-1+ of mestizos 
Hond [233] Prevalence EIA, WB 
0.3% HTLV-1+ 
Screening of healthy individuals from Tegucigalpa and San Pedro Sula. n = 899 
1.1% HTLV-2+ 




EIA, WB, PCR 0.24% HTLV-1+ Test of a new assay in blood donors. n = 410 
Cuba [215] Prevalence EIA, WB, RIPA 0.27% HTLV+ Screening of blood donors. n = 2579 
Cuba [216] Prevalence EIA, WB 0.99% HTLV-1+ blood donors Screening of blood donors (n = 1409) & risk groups. 
Cuba [214] Prevalence PA, EIA, IF, WB 
0.25% HTLV+ in blood donors Screening of blood donors (n = 2429) & patients with hematological and non-
hematological disorders from 13 provinces. 0.72% in patients 
Cuba [178] Prevalence EIA 4.2% HTLV-1+ Screening of archival samples from a previous oral cancer study. n = 379 
Cuba [220] CSS EIA, WB, PCR 5 ATLL reported 
Hematological neoplasms in 2 sentinel centers from Havana & Matanzas, (1997–
2006). n = 1281 
DR [218] Prevalence EIA, WB, RIPA, IFA 2.5% HTLV+ low risk group 0% Children Screening of low (n = 2552) and high risk populations. 
PR [219] Prevalence Undisclosed 0.25% HTLV+ Database search of transfusion transmitted pathogens in blood donors. n = 400 
PR [217] Prevalence EIA, WB, RIPA 
O.2% HTLV-1+ Archival samples from a Dengue surveillance study & blood donors from 
Ponce. n = 1881 1% IVDU 
Venez [236] Prevalence EIA, WB, PCR 0.2% HTLV+ Screening of blood donors from Caracas. n = 23,413 
Venez [237] Prevalence EIA 
1% HTLV+ Caracas 
Screening of healthy individuals. n = 769 
13.7% in the Amazonas 
Venez [238] Prevalence EIA, WB 0.58% HTLV+ 




Prevalence Undisclosed 0.3 % HTLV+ Databases search of Colombian blood banks (2001–2014). n = 5,105,159 
Colom 
[240] 
Prevalence EIA 0.24% HTLV+ Databases search of Cali blood banks (2008–2014). n = 77,117 
Prevalence PA, WB 0.7% HTLV-1+ children Screening of random subjects from Tumaco. n = 1077 








Prevalence EIA 0.3% HTLV+ Screening of blood donors from Bogota (1999–2004). n = 8913 
Colom 
[243] 
Prevalence EIA, WB 
0.176% HTLV+ 




Prevalence EIA, WB 
0.06% HTLV+ 




CSS EIA, RIA, WB 
4.3% HTLV+ lowland 
Comparison between Coastal and high-altitude towns. n = 670 
0.9% upland regions 
Colomb 
[246] 
Case report EIA HTLV+ ATLL HTLV+ ATLL co-presenting with a verrucous carcinoma 
Colom 
[247] 
Case Report EIA, WB, PCR Clinical presentation similar to ATLL from Japan Description of six ATLL patients from Cali. 
Colom 
[248] 
Case Report EIA, WB HTLV-1+ ATLL Description of two ATLL patients 
Colom 
[249] 
Case control EIA, WB 100% of TSP/HAM & ATLL cases were HTLV-1+ Screening for auto-antibodies in TSP/HAM (n = 37) and ATLL (n = 10) patients. 
Ecuador 
[250] 
Prevalence EIA, IF, WB 3.5% HTLV+ Screening of random subjects from the Esmeralda Province. n = 227 
Ecuador 
[251] 
Prevalence EIA, WB 2.4% HTLV+ in Afro descendant, 0% in the Chachis Screening of random subjects from the Esmeralda Province. n = 142 
Ecuador 
[252] 
Prevalence EIA, RIPA, WB 
0.42% HTLV-1+ in continental regions 
Screening of healthy individuals (n = 744) and risk groups throughout Ecuador. 
1.57% in Galapagos Island 
Peru [253] Prevalence EIA, WB 3.4% HTLV+ Databases search of blood banks from Abancay (2010–2015). n = 2895 
Peru [254] Prevalence EIA, WB 0.9% HTLV-1+ Databases search of blood banks from Arequipa in 2005. n = 2732 
Peru [255] Prevalence EIA, WB 
0.3% HTLV-1+ 
Screening of random subjects from 24 cities. n = 1535 
0% HTLV-2 
Peru [256] Prevalence EIA 1.7% HTLV-1+ Screening of pregnant women from Lima. n = 2492 
Peru [257] Case report Undisclosed HTLV-1+ Acute liver failure as presentation of ATLL. 
Peru [258] Case report Undisclosed HTLV-1+ Co-presentation of ATLL and strongyloidiasis. 
Peru [259] Case report WB HTLV+ Description of three ATLL patients. 
Peru [260] Case report EIA, WB 
3/7 tumors EBV+ 
Description of seven patients with DLBCL in HTLV-1 carriers. 
HTLV provirus in tumor was not assessed 
Peru [261] Case report EIA HTLV-1 HTLV-1+ Description of two cases of ATLL and concomitant S. stercoralis. 
Peru [262] Case report EIA, WB, IH HTLV-1+ Description of four patients with gastric ATLL 
Peru [263] Case Report EIA, PCR HTLV-1+ Description of one ATLL patient 
Chile [264] Prevalence EIA, IF, PCR 
0.12% HTLV+ Databases search of blood banks from 12 Chilean regions (2011–2013). n = 
694,016 HTLV-1: HTLV-2 (7.3:1) 
Chile [265] Prevalence EIA, IF, PCR 
0.24% HTLV-1+ 
Databases search of blood banks from Valdivia (May 2009–May 2010). n = 6237 
Female:Male (3:1) 
Chile [266] CSS EIA, SB, PCR Clinical and laboratory features of HTLV-I+ ATLL Description of ATLL patients from the Santiago area (1989–1998). n = 26 
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Chile [267] Case report EIA, PA, PCR 
Intestinal involvement and progression into a leukemic 
phase 
Description of one ATLL patient 
Chile [268] Case report EIA, SB, PCR Clinical and laboratory features of HTLV-I+ ATLL Description of nine ATLL patients 
Chile [269] Case report EIA, WB Provirus was not assessed Description of an ATLL with Reed-Sternberg cells 
Chile [270] Case report EIA, WB, SB HTLV-1+ ATLL Description of three ATLL patients co-presenting with TSP/HAM 
Chile [271] Case report EIA, CSF, SB HTLV-1+ ATLL ATLL case preceded by TSP/HAM 
Chile [272] Case report EIA, SB HTLV-1+ ATLL Chilean immigrant in Spain with ATLL 
Chile [273] CSS PCR, RFLP 18.2% HTLV+ (15 HTLV-1 & 1 HTLV-2) Analysis of hematological malignancies from Valdivia. n = 88 
Chile [274] CSS Undisclosed 
23 neoplasia of T cells 
Analysis of chronic LPD from one hospital in Santiago (1999–2001). n = 132 
11 HTLV-1+ ATLL 
Chile [275] Case report WB HTLV+ ATLL ATLL case in an HIV+ patient 
Parag [276] Prevalence PA, EIA, WB, RIPA 0% HTLV+ healthy Screening of healthy volunteers (n = 338) and risk groups. 
Urug [277] Prevalence EIA 0.13% HTLV+ Data from the National Registry Report of blood banks, 2012–2014. n = 297,371 
Urug [278] Prevalence PA, IFA, WB, RIPA 0.75% HTLV-1+ Screening of blood donors (n = 266) and risk groups. 
Urug [279] Case report Undisclosed HTLV-1+ ATLL of a Peruvian immigrant co-presenting with multiple parasitosis. 
Arg [280] Prevalence PA, EIA, WB 
0.9% HTLV-1+ 
Databases search of blood banks from Jujuy city. n = 14,228 
0.04% HTLV-2+ 
Arg [281] Prevalence EIA, PA, IFA, WB 
0.05% HTLV-1+ 
Databases search of blood banks from Buenos Aires. n = 12,891 
0.03% HTLV-2+ 
Arg [282] Prevalence 
EIA, PA, WB, 
Phylogenetic study 
0.011% HTLV-1+ 
Databases search of blood banks from Corrientes. n = 9422 
0.021% HTLV-2+ 1 
HTLV-1 Subtype A 
HTLV-2 Subtype B 
Arg [283] Prevalence EIA, PA 0.11% HTLV+ Database search of a blood bank from Cordoba. n = 20,210 
Arg [284] CSS EIA, PA, WB 
0.028% HTLV-1+ 
Databases search of blood banks from 9 different provinces. n = 123,233 
0,025% HTLV-2+ 
Arg [285] Prevalence PA, IF, WB, PCR 0.19% HTLV-1/2+ Databases search of blood banks from Buenos Aires. n = 2050 
Arg [286] Prevalence PA, WB 0.06% HTLV-1+ Databases search of blood banks from Buenos Aires. n = 12,846 
Arg [287] Prevalence PA, WB 
0.036% HTLV-1+ 
Databases search of blood banks from Buenos Aires. n = 19,426 
0.01% HTLV-2+ 
Arg [288] Prevalence PA, WB 
0.035% HTLV-1 
Databases search of blood banks from Buenos Aires. n = 28,897 
0.007% HTLV-2 
Arg [289] Prevalence PA, IF 0.26% HTLV-1 Databases search of blood banks from Cordoba. n = 5476 
Arg [290] Prevalence PA, IF, WB 0% HTLV-1 Databases search of blood banks from Santa Fe and Santiago del Estero. n = 1327 
Arg [291] Prevalence PA, EIA, WB, PCR 
0.033% HTLV-1+ 
Databases search of blood banks from Buenos Aires. n = 76,246 
0.013% HTLV-2+ 
Arg [292] Prevalence Undisclosed 
1.0% HTLV+ Jujuy 
Databases search of blood banks from Northern and Center regions. n = 130,599 0.7% HTLV+ Salta 
0.6% HTLV+ Formosa 
Arg [293] Prevalence PA, WB, PCR 
0.034% HTLV-1+ 
Databases search of blood banks from Buenos Aires. n = 86,238 
0.014% HTLV-2+ 
Arg [294] Prevalence PA, WB 
0.03% HTLV-1+ 
Databases search of blood banks from Santa Fe. n = 9425 
0.05% HTLV-2+ 
Arg [295] Prevalence EIA, PA, WB 0.00072% HTLV+ Databases search of blood banks from Misiones. n = 6912 
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Arg [296] Prevalence EIA 
0.07% HTLV-1+ 
Databases search of blood banks from Buenos Aires. n = 28,483 
0.03% HTLV-2+ 
Arg [297] Prevalence EIA 0.191% HTLV+ Screening of pregnant women from Córdoba. n = 3143 
Arg [298] Prevalence 
PVT, IH, Proviral DNA 
integration 
5 cases HTLV-1+ from native American: ATLL 34 cases of lymphoma resembling ATLL 
Arg [299] Case Report Undisclosed 
HTLV-1+ of Guinean origin 
Association of B-cell lymphoma and T-cell lymphoma in HTLV-1 infection. 
NHL B and one T without phenotype of ATLL 
Arg [300] 
Case report 
Undisclosed HTLV-1+ ATLL cases 
5 cases 
Arg [301] 2 cases report Undisclosed HTLV-1+ ATLL from 2 asymptomatic brothers 
Brazil [302] Prevalence EIA, PCR 
0.1% HTLV+ 
Databases search of blood banks from Riberao Preto, Sao Paulo. n = 301,400 
HTLV-1:2 (2:1) 
Brazil [303] Prevalence EIA, WB 
0.04% HTLV+ in South 
Databases search of blood banks from 27 urban cities. n = 6,218,619  
1% in Northeast 
Brazil [304] Prevalence EIA, WB, PCR 1.76% HTLV-1+ Subtype A Databases search of blood banks from Salvador. n = 1385 
Brazil [305] Prevalence EIA, WB 0.08%-0.2% HTLV+ 
Databases search of blood banks from Sao Paulo, Minas Gerais & Pernambuco. n 
= 281,760 
Brazil [306] Prevalence EIA 0.63% HTLV+ Databases search of blood banks from Southwest Bahia. n = 34,400 
Brazil [307] Prevalence EIA 0.09% HTLV+ Databases search of blood banks from Goiás. n = 137,209 
Brazil [308] Prevalence EIA 
0.77% HTLV-1+ 
Databases search of blood banks from Salvador Bahia. n = 233,876 
0.025% HTLV-2+ 
Brazil [309] Prevalence PCR 
1.4% HTLV-1 
Databases search of blood banks from Belém, Pará. n = 1059 
0.5% HTLV-2 
Brazil [310] Prevalence EIA, PCR 
0.059% HTLV-1+ 
Databases search of blood banks from Piauí. n = 37,306 0.037% HTLV-2+ 
HTLV-1 subgroup A 
Brazil [311] Prevalence EIA, WB 0.13% HTLV+ Databases search of blood banks from Manaus. n = 87,402 
Brazil [312] Prevalence EIA 0.58% HTLV+ Databases search of blood banks from Marajó Island. n = 1899 
Brazil [313] Prevalence EIA 1.48% HTLV-1+ Databases search of blood banks from Salvador Bahía. n = 3451 
Brazil [314] Prevalence EIA 
0.019% HTLV-1+ 
Databases search of blood banks from Fortaleza. n = 679,610 
0.005% HTLV-2+ 
Brazil [315] Prevalence EIA 0.1% HTLV+ Databases search of blood banks from Minas Gerais. n = 3,249,944 
Brazil [316] Prevalence EIA 0.02% HTLV+ Databases search of blood banks from Uberata. n = 147,489 
Brazil [317] Prevalence EIA 
0.1% HTLV-1 
Databases search of blood banks from Belo Horizonte. n = 422,600 
0.002% HTLV-2 
Brazil [318] CSS EIA 0.02% HTLV+ Databases search of blood banks from Riberao Preto. n = 377,243 
Brazil [319] Prevalence EIA, WB 0.15% HTLV+ Databases search of blood banks from Maranhao. n = 365,564 
Brazil [320] Prevalence EIA, WB 0.66% HTLV+ Databases search of blood banks from Rio Branco. n = 11121 
Brazil [321] Prevalence EIA 0.3% HTLV+ Databases search of blood banks from Sao Paulo. n = 351,639 
Brazil [322] Prevalence EIA, WB 0.17% HTLV+ Databases search of blood banks from Sao Paulo. n = 17063 
Brazil [323] CSS Undisclosed 
83 ATLL (26 smoldering, 23 chronic, 16 acute, 13 
lymphoma and five primary cutaneous) 
ATLL treatment and response in Salvador, Bahia 
Brazil [324] CSS EIA, WB, PCR, IH HTLV-1+ 52 cases ATLL from Salvador, Bahía. 
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Brazil [325] Case report EIA, WB, IH HTLV-1 in CSF + ATLL 
Simultaneous development of ATLL and HAM/TSP in a pediatric patient with 
IDH. 
Brazil [326] CSS EIA, WB HTLV+ ATLL Prognostic Factors of 72 ATLL. 
Brazil [327] Case report EIA, WB, Nested PCR HTLV-1+ ATLL with monoclonal integration. ATLL case 
Brazil [328] Case report 
EIA, WB, PCR 
HTLV-1+, four with p16 deletion, one with p53 mutation 8 cases of pediatric ATLL patients 
FC, Cytogenetic 
Brazil [329] CSS EI,A WB, Nested PCR HTLV-1+ found in 48 ATLL. 188 patients with a T-cell disorder. 53 ATLL. Rio de Janeiro, Brazil 
Brazil [330] Cohort EIA, PA, WB, Sequencing HTLV-1+ found in 11 cases. 14 cases of ATLL, Rio de Janeiro. 
Brazil [331] Case report EIA HTLV-1+ Hodgkin-like ATLL from Salvador, Bahía. 
Brazil [332] Case report EIA HTLV-1+ ATLL from Brasilia. 
Brazil [333] Case report EIA HTLV-1+ ATLL with Hyalohyphomycosis 
Brazil [334] Case report EIA HTLV-2+ Two HTLV-2+ ATLL cases in Maranhao, Northeast Brazil. 
Brazil [335] Case report EIA HTLV-1+ ATLL in a patient with Strongyloides stercoralis. 
Brazil [336] Case report EIA HTLV-1+ IDH progressing to ATL. 
Brazil [337] Case report EIA HTLV-1+ Primary cutaneous type of ATLL. 
Brazil [338] Case report EIA HTLV-1+ 2 ATLL cases from Minas Gerais. 
Brazil [339] Case report EIA HTLV-1+ ATLL case. 
Brazil [340] CSS EIA, WB, PCR 
HTLV-1+ 
195 ATLL cases from Rio de Janeiro. 
9% also with HAM/TSP 
Brazil [341] CSS EIA, PCR HTLV-1+ 28 ATLL from Bahía. 
ATLL adult T leukemia/lymphoma; CSS: cross sectional study; DLBCL: diffuse large B-cell lymphoma; EIA: enzyme linked immunoassay; FC: flow cytometry; HIV: 
human immunodeficiency virus; HSCS HTLV-I/II-associated spinocerebellar syndrome; IF: immunofluorescence; IDH: infective dermatitis associated with HTLV; 
IDU intravenous drug users; IH: immunohistochemistry; LG: lymphomatoid granulomatosis; MF: mycosis fungoides; PA: particle agglutination; PTCL: peripheral 
T-cell lymphoma; RFLP restriction fragment length polymorphisms; RIPA: radioimmunoprecipitation; SB: Southern blot; SS: Strongyloides Stercoralis infection; 
TSP/HAM: Tropical spastic paraparesis/HTLV associated myelopathy; WB: western blot. 
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Zero to 0.39% HTLV positivity and no ATLL were found from Mexico [226,228,342,343]. 
Interestingly, in those studies in which subtypes were identified, HTLV-2 was the only or the most 
prevalent one [344–347]. In agreement, HTLV-2 was highly prevalent in IVDUs (22%) [346]. From 
Central American countries, 5% HTLV-1 positivity has been found in the metropolitan areas of 
Panama City and Colon [229], and 0.24% and 0.68% HTLV-1 positive cases in Nicaragua and Costa 
Rica, respectively [235,348]. Honduras exhibited significant differences between regions, namely a 
0.3–1.1% prevalence reported in the Central capital of Tegucigalpa and in the North West of the 
country, compared to a higher prevalence observed in coastal cities, particularly among black natives 
(17.7%) and non-mestizos (8.1%) [232,233,349]. High prevalence of 8.3–9% has also been reported 
among indigenous populations of Panama, all carrying HTLV-2. Although multiple cases of 
TSP/HAM have been reported, mostly associated with HTLV-1 infection [349–353], only five ATLL 
cases have been reported in Central American countries, one associated with HTLV-1 infection and 
the others of an unknown etiology [230,231,234]. 
Screening for HTLV infection in blood banks is mandatory in several South American countries; 
Brazil has done it since 1993, Peru since 1998, Uruguay since 2000, Argentina since 2005, Chile since 
2009 and Colombia since 2014. This has allowed for studies based on a large number of samples, and 
for a more factual estimation of HTLV prevalence. In Caracas, Venezuela a 0.2% HTLV positivity and 
a rate HTLV-1: HTLV-2 of 11:1 was observed [236]. Other similar studies also found low HTLV 
positivity in Maracay (0.58%) and in Caracas (1%), but higher in the Amazon region (13%) [237,238]. 
A study that included all Colombian departments found an overall seropositivity of 0.3%, with most 
departments below 1% and Chocó being the only exception with 6.28% [239]. Similar studies from 
several blood banks from Medellin observed 0.06–0.176% positivity, mainly for HTLV-1 [243,244]. 
We also found two studies conducted on blood donors from Peru, Arequipa (0.9% HTLV-1 positive) 
and Abancay (3.4%, unknown subtype), and one in pregnant women from Lima (1.7% HTLV-1 
positive) [253,254,256]. Concerning Chile, 0.12–0.24% HTLV positivity was described, showing 
higher prevalence in the central region of Valdivia than in Concepcion in the South; together with an 
almost 3:1 female to male ratio and a 7:1 HTLV-1 to HTLV-2 ratio [265,274]. A 0.13% HTLV positivity 
was found in Uruguay, ranging from 0.2% in the North to 0.09% in the South [277]. Those studies 
that were not based on archival data taken from blood donors reported an HTLV seropositivity of 
0.42% in continental Ecuador, 1.57% in the Galapagos Island [252] and 2.4–3.5% for Afro-descendants 
from the Esmeralda province [250,251], 4.3% HTLV-1 in Bolivia [354] and 0% HTLV positives [276] 
to 2.5% HTLV-2 in Paraguay [355]. Figure 6 summarizes studies about the HTLV prevalence among 
LA countries. 
 
Figure 6. HTLV prevalence. Numeric values are in percentage. ND: not determined. 
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Multiple studies have addressed HTLV prevalence in Brazil and Argentina revealing regions of 
high endemicity. In the former, the highest prevalence was demonstrated in the North-North East 
region, in particular in Salvador de Bahia, ranging from 0.046% to 1.8% [303,306,308–
310,312,313,319,320,356–366], with slightly higher prevalence in specific villages with African 
characteristics, such as Piaui (2.24%) [359], Taquarendi (3.85%), Junco (1.23%), Alegre (1.56%) [363] 
and Marajó Island (1%–2.06%) [366]. In the South and South Eastern regions, HTLV prevalence 
ranged from 0.02% to 1.5% [302,303,305,318,321,322,358,367–370]. In urban Northern and Southern 
regions HTLV-1 prevailed over HTLV-2 [309,310,313,314,317,358]. The central region exhibited HTLV 
prevalence ranging from 0.02% to 1.6% [305,307,315–317,371–374], of which, for the Amazonian 
region, prevalence increased when indigenous villages were analyzed: 0.4–1.18% HTLV positivity in 
the city [375–378], whereas, in certain villages, the prevalence increased up to 13.88% [376,379–383]. 
In Argentina, most seroepidemiological studies were performed in the North and central regions, 
and an HTLV-1 endemic area was discovered in Jujuy, a North Western province. HTLV prevalence 
in central provinces ranged from 0% to 0.2% (0.028–0.26% HTLV-1; 0.007–0.03% HTLV-2) 
[281,282,284,285,287–292,294–296,384]. In contrast, this incidence is increased up to 9.8% of HTLV-1 
in Jujuy [280,292,385,386], and to 31.5% when Jujuy family clusters were studied [387]. Surprisingly, 
other Northern Argentinean cities reported low HTLV positivity, namely 0.16–0.7% in Salta that 
borders with Jujuy [284,292], 0.6% in Formosa [292] and 0.007% in Misiones [295]. In the above-
mentioned epidemiological studies, HTLV positivity seems enriched in populations with a high 
proportion of Amerindians, particularly for HTLV-2. Additionally, a higher prevalence of 17–19% 
was found among first generation Japanese immigrants, particularly those coming from the HTLV-1 
endemic region of Kyushu [354,388]. Second and third generation Japanese-Bolivians were 6% HTLV-
1 positive, closer to the native Bolivian population. HTLV prevalence has also been addressed in 
Japanese immigrants in Brazil (1.8–6.8%) and their descendants (0.73%) [361,389,390]. See Table 5 for 
HTLV prevalence in other risk groups. 
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Table 5. HTLV in risk groups. 
Country (Ref) 
HTLV Prevalence Risk Groups 





NT = 531/8154 
(6.5%) 
n = 96 (H-1) 
n = 69 (H-2) 
0.5% 
NT = 2/395 
n = 2 (H-1) 
1.4–3.2% 
NT = 31/1336 (2.3%) 
n = 30 (H-1) 
n = 1 (H-2) 
0.7–4.7% 
NT = 38/1871 
(2%) 
n = 9 (H-1) 
 
11.7–35.2% 
NT = 165/854 
(19.3%) 
n = 78 (H-1) 
n = 28 (H-2) 
7–10.2% 
NT = 41/422 
(9.7%) 
n = 41 (H-1) 
21.2–35.1% 
NT = 159/517 
(30.7%) 
n = 159 (H-1) 
Argentina [387,409–418] 
1.6–27.7% 
NT = 114/1158 (9.8%) 
n = 59 (H-1) 
n = 18 (H-2) 
1% 
NT = 4/400 
1.5–1.6% 
NT = 17/1069 (1.6%) 
n = 6 (H-1) 
n = 1 (H-2) 
0.5–3% 
NT = 26/1216 (2.1%) 
n = 2 (H-1) 
 
1.5–33.6% 
NT = 149/1128 
(13.2%) 
n = 69 (H-1) 
n = 47 (H-2) 
 
31.5% 
NT = 29/92 





NT = 31/642 (4.8%) 
n = 4 (H-1) 
n = 24 (H-2) 
 
0–1.8% 
NT = 7/462 (1.5%) 
n = 0 (H-1) 
n = 5 (H-2) 
0–0.9% 




NT = 9/195 (4.6%) 
20.7% 
NT = 106 
0–0.8% 




NT = 6/108 
2.8% 
NT = 14/494 
4.2% 
NT = 13/308 
  
2–14.3% 





NT = 0/268 
1.7% 
NT = 25/1444 
n = 25 (H-1) 
    
10% 
NT = 29/921 
n = 29 (H-1) 
 
Venezuela [424]   
0% 
NT = 0/141 
1% 
NT = 1/100 n = 1 (H-1) 
    
Ecuador [252]  
0.6% 
NT = 1/159 
n = 1 (H-1) 
1.4% 
NT = 2/141 
n = 2 (H-1) 
     
CR [348]     
0.7% 
NT = 3/436 
n = 3 (H-1) 
   
Colombia [241]      
7.8% 
NT = 13/167 
n = 13 (H-1) 
  
Peru [425]   
9.5% 
NT = 184/1938 
n = 184 (H-1) 
     
Prevalence of HTLV infection in specific risk groups, the range of positives and the value of the number of positives/total of tested individuals (NT) are given as 
percentages. Data based on one single study does not include a range. When the study addressed the HTLV type, the number of positives (n) found for HTLV-1 (H-
1) or HTLV-2 (H-2) are also given. FSW: female sex workers, STD: sexually transmitted diseases, MSM: men that have sex with men, IVDU: intravenous drug users. 
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While the most pathogenic HTLV-1 strain is more prevalent among urban mestizo, Afro-
descendants and Caucasian populations, HTLV-2 seems to be more prevalent among some 
Amerindian tribes. Interestingly, different endemic zones for HTLV-1 and HTLV-2 infections have 
been described among different tribes of Colombian Amerindians [426–429], with a general higher 
HTLV-1 prevalence in tribes from the Andes and other highlands than in lowlands, and vice versa 
for HTLV-2. Likewise, the Peruvian Andeans such as the Quechua exhibit 2.8–5.1% HTLV-1 positivity 
and 0% HTLV-2 [430,431]. The exceptions of Amazonian communities with an almost exclusive 
HTLV-1 infection are the Shipibo-Konibo (1.9%), the Wayku (2.5%) and San Francisco (1.4%) 
[432,433]. In Chile, higher prevalence was also found in Amerindian tribes than in mestizo urban 
populations, with those from the highland Atacama region exhibiting the highest positivity with 
6.5%, while Mapuches were 0.7–1%, Huilliches were 1.9% and natives from the island of Chiloe and 
Pitrufquen town in the South of Chile were 1.5% [434–436]. Additionally, in those studies in which 
the viral strain has been addressed, an almost exclusive presence of HTLV-1 was found [434,436]. 
HTLV-1 infection among Bolivian Amerindians was 5.3% in the Aimara and 4.5% in the Quechua 
[437]. Other Amerindian populations outside the high endemicity region of the Amazonia, such as 
Guaranies, Kayapo and Kraho tribes, showed HTLV prevalence of 5.7%, 33.3% and 12.2%, 
respectively [438,439]. It is worth mentioning that, while the HTLV-1 prevalence was below 11% in 
endemic regions, HTLV-2 prevalence was significantly higher [428,429]. An international study that 
analyzed Indians from Colombia, Venezuela, Bolivia, Brazil, Paraguay and Chile found HTLV-2 
positivity of up to 57.9% in the Kayapo, Brazil, 34.8% in Alacalf, Chile and 16.4% in the Chaco, 
Paraguay [437]. Higher HTLV-2 positivity has also been demonstrated for Amerindians populations 
from Argentina, such as the Toba (10–36.4%), Gran Chaco (22%), Mataco (3%) and Mapuches (2%) 
[284,290,385–387,412,437,440–443]. Other Amerindians that exhibited an almost exclusive HTLV-2 
prevalence were those from the Gran Chaco region of Paraguay (4–44%) [355,442], Boca Colorado 
(4.54%) and Galilea (2.38%) in Peru [443] and the Yaruro/Guahibo (24.8–61%) and the Pume (5%) in 
Venezuela [444–446]. Of note, ethnic groups with 0% positivity to both types have been described in 
Venezuela, Colombia, Ecuador and Bolivia [251,426,437]. Figure 4 maps the prevalence of HTLV-1 
and HTLV-2 among the Amerindian populations. 
There are multiple reports of ATLL in South America, mostly describing a disease with similar 
features to Japan ATLL, but in younger individuals. In Colombia, 19 HTLV positive ATLL cases have 
been reported, 12 confirmed as HTLV-1, while, in the others, the HTLV subtype was not investigated 
[246–249]. On the other hand, about 200 of TSP/HAM cases have been documented, with half of them 
confirmed to be in HTLV infected individuals [249,447–451]. It is also notable that many cases come 
from the Tumaco district, in which TSP/HAM was originally described and in which a 5.3% HTLV-1 
positivity has been reported among adults [241]. Furthermore, 12 ATLL cases from Peru and an 
additional case of a Peruvian immigrant in Uruguay were described, all of them being fatal [257–
259,261–263,279]. These ATLLs displayed common features, since half of them had gastrointestinal 
tract compromise, and half of them occurred in individuals younger than 50 yr, including a 20 yr 
female. There were also seven DLBCL developing in HTLV-1 seropositive patients, but in which, the 
presence of the provirus was not assessed [260]. The tumor cell also harbored EBV in three of these 
DLBCLs. As an HTLV endemic country, Peru reports large cohorts of TSP/HAM reflecting a common 
disease [452–455], and also cases in which HTLV infection correlates with infective dermatitis [456], 
including children in which neurological disorders co-exists with infective dermatitis [457] and 
Strongyloides stercoralis [458,459]. Fifty-four cases of ATLL have been reported from Chile [266–
272,275]. Highlights are the early presentation, with medians of 50 yrs and 51 yrs for the largest 
cohorts [266,268], and an onset concomitant with or proceeded by TSP/HAM. It is also interesting to 
point out that all reported cases in large cohorts are of Caucasian origin (49/49) [266,268,270]. 
Barrientos A, et al. found HTLV positivity by PCR in 16/88 (18.2%) cases of hematological 
malignancies (15 HTLV-1 and 1 HTLV-2), including two of myeloid origin. The median age of 
diagnosis was 33 yrs (2–92 yrs), with 50% of HTLV positive patients being 30 yrs or younger. No 
ATLL assignation was given in this study [273]. Multiple cases of TSP/HAM are also reported from 
Chile [460–463], but, contrary to ATLL, TSP/HAM occurs in Caucasians, in mestizo and Chilean 
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Amerindians. There were no reports of other HTLV-associated diseases. In Argentina, ATLL cases 
have been described in the highly endemic Jujuy, with five cases with confirmed diagnoses [298]. 
There are seven other ATLL cases reported (two originating in brothers) [300,301]. In addition, 
TSP/HAM cases have been described in Aymara Amerindians, also in Jujuy [464], and also in 
Caucasian patients from other non-endemic regions [465–468]. Figure 7 shows an example of an 
ATLL with a CD4+CD25+FOXP3+ regulatory T cell phenotype. 
 
Figure 7. Adult T cell lymphoma (ATLL) of CD4 T cells. (A) Hematoxylin-Eosin staining. (B) CD3 
staining. (C) CD4 staining. (D) CD8 staining. (E) CD25 staining. (F) FOXP3 staining. Magnification A, 
B, C, D and F 40×, E 10×. 
The number of ATLL and TSP/HAM cases reported from Brazil is in agreement with a country 
of high HTLV endemicity. For instance, ATLL cases have been reported in the urban areas of North 
East Brazil, by and large in the Bahía state that presents the largest prevalence of HTLV-1 infection 
[326,327,333,335,336,469–471]. Characteristics of these ATLL are that they displayed cutaneous 
involvement [323,324], or were associated with infective dermatitis (IDH) [336], hyalohyphomycosis 
[333], Strongyloides stercoralis [335] or Hodgkin-like features [332]. Remarkably, ATLL has also been 
described in 31 pediatric patients [472]. In the South of Brazil, most reports are from Rio de Janeiro, 
where ATLL features often included a primary cutaneous type presentation [330,340,394,406], 9% (of 
195 patients) co-presented with TSP/HAM [340], and eight cases were in pediatric patients [328]. 
There are at least 27 articles describing TSP/HAM cases that also support a common disease. 
TSP/HAM incidence was increased in HTLV-1 and HIV positive individuals (18–30%) versus those 
who were only HTLV positive (1.93%) [473,474], and pediatric cases of TSP/HAM have also been 
reported [472]. HTLV infection was also associated with IDH [475] and other dermatologic [476–480], 
oral [481], ocular [482] and neurologic [483] complications. Although there are multiple reports of 
TSP/HAM from Venezuela, Ecuador, Uruguay and Paraguay, we could not find a single report of 
ATLL in these countries. 
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HTLV-1A has been found throughout South America [282,304,484–487]. On the other hand, 
Amerindians with high HTLV-2 prevalence almost exclusively carry the HTLV-2B genotype 
[442,445,446,488,489]. HTLV-2B was also the prevalent genotype in Mexico [345,420] and Panama 
[490], while HTLV-2A [491] and -2C [492] have been found in Brazilian Amerindians co-infected with 
HIV, and HTLV-2A in healthy Kayapo Amerindians [493]. This is important because, although 
published studies support a relative high incidence of ATLL in South American countries, the disease 
seems most prevalent among mestizo and Caucasian populations than among Amerindians, despite 
their higher HTLV-2 positivity. 
5. Discussion 
The association between EBV infection and lymphoma varies worldwide. The most compelling 
observation is the higher incidence of EBV-positive cHL in LA than in industrialized countries, and 
also the relationship between the age at which EBV primo-infection occurs and the onset of cHL. In 
underdeveloped and developing LA populations, earlier exposure to EBV in the face of a relatively 
underdeveloped immune response might be a predisposing factor for EBV-positive cHL. 
Socioeconomic improvement in Brazil turned into a decreased incidence from 87% to 46% in a 54 year 
period [32]. A similar picture emerges for EBV-positive BL, since this disease shows features of 
endemic BL in particularly underdeveloped regions, for instance, 76–100% in North Brazil [36,56], 
while it resembles more the sporadic form in the South of Brazil, Chile and Argentina [114]. Fewer 
driver mutations, especially among genes with roles in apoptosis, were demonstrated in EBV-
positive BL from USA and Uganda, suggesting a specific BL phenotype, irrespective of geographic 
origin [494]. Particular pathogenic mechanisms may predispose against EBV-positive cHL and EBV-
positive BL, such as ethnicity, endemic infectious agents, low age of seroconversion or differences in 
socioeconomic development. 
EBV-associated T and NK LPDs represent a broad spectrum of diseases that occurs with higher 
incidence in Asian and LA populations. The incidence of these lymphomas in LA should grant EBV1 and 
EBV2 prevalence studies, particularly for Mexico and Peru, in which this lymphoma is highly prevalent. 
NKT LPDs often emerge within CAEBV disease in which infection of T- or NK- cells apparently occurred 
during primary infection. Genetic alterations are rare in CAEBV, but mutations in DDX3X, KMT2D, 
BCOR, BCORL1, TET2 and KM6A have been identified [495]. Likewise, LA has shown slightly higher EBV 
association frequencies in DLBCL, particularly in Peru. Peru has also reported cases of systemic EBV-
positive T-cell lymphoma of childhood [99]. Gene expression profiling shows that EBV-positive DLBCL 
NOS, is molecularly distinct from EBV-negative DLBCL in Western developed populations, with NFκB 
p50, STAT-3 and CD30 more commonly expressed in EBV-positive DLBCLs [496]. No genetic study has 
been conducted in DLBCL of Hispanic patients so far. 
ENKTL represents around 23% of all T-cell lymphomas in LA (up to 40% in Mexico and 66% in 
Guatemala), compared with 4% to 5% in Europe and the United States. The clinical presentation is 
similar in all geographic regions; however, patients in LA tend to present with more advanced clinical 
stages [497]. In the ENKTCL arising in East Asia, genetic analyses have shown that activating 
mutations of the JAK-STAT pathway, such as in JAK3 (5–35%), STAT3 (6–27%) and STAT5B (2–6%) 
genes are characteristic of this lymphoma [498,499]. Other mutations include the RNA helicase 
DDX3X, the tumor suppressor gene TP53, as well as genes encoding proteins involved in epigenetic 
pathways (MLL2, ASXL3, ARID1A and EP300) [134]. In a study of 71 ENKTCL cases from three 
different centers in LA (42 from Mexico, 17 from Peru and 12 from Argentina), mutations affecting 
the JAK-STAT signaling pathway were identified in 27% of cases, being STAT3 the most frequently 
mutated gene (22%). Mutations in BCOR, DDX3X  and TP53 were also identified, but with different 
frequencies than in Asian cohorts [500]. These data indicate that ENKTCL shows a similar mutational 
landscape in LA and Asia. 
With respect to KSHV, available reports based on healthy populations and risk groups make it 
possible to infer an LA prevalence higher than in the US and non-Mediterranean Europe but lower 
than endemic regions of Africa and the Mediterranean. With the exception of Chile, LA exhibits 
global frequencies above 3%, and particularly above 10% for Cuba, Colombia, Argentina (San 
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Salvador Jujuy), Ecuadorian Afro-descendants and Peru. Indeed, large KS series (e.g., ≥ 50 cases) from 
Cuba, Colombia and Peru have been published [184,501,502], including a series of cases of cKS 
published before the HIV/AIDS era, and of pediatric KS [503]. KS has also been documented as the 
third most common neoplasm in Peru [504]. 
In Amerindian tribes in which the KSHV genotype E is endemic, viral transmission starts very 
early, with 35 to 65% seropositives by age 10 [150,196,197,505], supporting casual contacts between 
family members as an important via of viral dissemination. Indeed, close contacts of KS patients have 
higher KSHV prevalence than the general population (Table 3). A similar scenario is found for HTLV, 
with seroprevalences increasing with age [442,506]. A study of 104 mothers with TSP/HAM showed 
that 19–31% of their children were already HTLV seropositive [454], supporting an early mechanism 
of vertical transmission, such as breast feeding, which could explain the pediatric presentation of 
ATLL and TSP/HAM in LA HTLV endemic zones. On the contrary, among non-endemic populations, 
the high prevalence among MSM and FSW supports sexual transmission as an important route for 
KSHV dissemination (Table 5). However, the latter is not as clear for HTLV infection, since those 
studies based on people attending STD clinics (0.6–2.8%), FSW (below 5% in most studies) and MSM 
(2% and below) reported lower frequencies than those observed for KSHV. An important exception 
is HTLV transmission among IVDUs that is consistently high (7.8–20.7%) in LA countries, with a 
notable higher prevalence of HTLV-2, and also in blood transfused individuals (0.4–10%), supporting 
contaminated blood as an important source for viral transmission. It is worth mentioning a study 
from Venezuela, in which three of five organ recipients from an HTLV-1 positive multi-donor became 
seropositive [507]. 
While ATLL among Amerindians is very rare, TSP/HAM is commonly reported. TSP/HAM was first 
described in the Southern Pacific of Colombia in 1981 as a chronic non-hereditary spastic paraparesis, 
initially termed Pacific spastic paraparesis [508], later also observed in the Caribbean islands of Martinique 
and Jamaica and in HTLV endemic regions of Japan. TSP/HAM seems to be highly prevalent in LA, 
particularly for Afro-descendants, but also for mestizo and Caucasian populations 
[223,249,351,448,449,452–455,461,464,472,509]. Likewise, infective dermatitis, strongyloidiasis and many 
other dermatological, oral, ocular and neurological complications are usually found co-presenting with 
ATLL or TSP/HAM, or independent of those diseases in HTLV endemic regions of Peru, Chile and Brazil. 
Infective dermatitis and strongyloidiasis sometimes precede TSP/HAM or ATLL [248,325,456]. It is also 
worth mentioning that extensive series of pediatric TSP/HAM have been reported from Salvador de Bahia 
and Rio de Janeiro in Brazil and in Peru [457,472]. All these studies pointed out that South America 
represents a major endemic area for HTLV infection and associated diseases. Remarkably, Mexico did not 
report HTLV positive ATLL or TSP/HAM. 
Reports of ATLL series were found only for Brazil and Chile (see Table 4), which makes it 
difficult to identify the unique features of the disease presentation in our population. Furthermore, 
most case reports lack molecular and serological methods to confirm HTLV infection. Nevertheless, 
during the review process those cases in which the neoplasm co-presented with TSP/HAM, infective 
dermatitis or strongyloidiasis, or with the characteristic flower cell, were assumed to be bona fide 
ATLL. However, absence of confirmatory tests may miss early ATLL, for instance, in the smoldering 
stage, in which there is no significant lymphocytosis. Still, there do not seem to be major clinical 
differences between the ATLL cases in LA and those from Japan, or from other parts of the world 
[340]. Perhaps the most distinctive feature is an early presentation. Iwanaga et al. reported that in 
Brazil the median age of presentation is 44 yrs, while in Japan it is 68 yrs [510], and, in spite of being 
named as an adult disease, there are pediatric cases of ATLL in Brazil [323,325,328,340,471]. The 
Chilean ATLL cohort also had a younger disease presentation than Japan, with a median age of 50 
yrs [266]. Most studies also support a poor prognosis for ATLL, the study of 195 cases from Brazil 
found an overall survival of 9.2 months [340]. 
6. Conclusions 
We observed a high incidence of EBV-positive lymphomas of T/NK cell origin for Mexico and 
Peru and of BL for North Brazil. Peru also carries the highest frequency of EBV-positive HL and 
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DLBCL than any other LA country. The presentation of HL and BL was also earlier than for 
industrialized countries, coinciding with an early EBV primo-infection, in spite of there being no 
evidence of infectious mononucleosis in the region. High prevalence of KSHV and HTLV was found 
among Amerindian populations, with different distributions between low-land (e.g., the Amazons) 
and high-land (e.g., the Andes) tribes. In spite of this, there were only scarce reports of MCD, PEL 
and ATLL. However, Peru reports KS as its third most common neoplasm. 
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